Concurrent validity and longitudinal responsiveness of a smartphone-derived disease activity measure in rheumatoid arthritis using clinician-assessed DAS28 as the reference standard
Abstract
To evaluate the concurrent validity, numerical agreement and longitudinal responsiveness of a smartphone-derived Digital Disease Activity Score (DDAS) against clinician-assessed DAS28 in patients with rheumatoid arthritis.
A prospective, comparative study was conducted during routine rheumatology care in Lahore, Pakistan. Participants completed a structured digital questionnaire and four guided smartphone movement assessments. A trained rheumatologist independently completed the DAS28 reference assessment using ESR or CRP. All participants included in the principal analysis had a documented inflammatory marker and a complete DAS28 dataset. Primary outcome was to compare DDAS and DAS28 values and secondary analyses of threshold performance and change between repeat visits.
A total of 113 paired assessments from 61 unique participants, of whom 31 contributed repeat observations, yielding 52 within-participant transitions. DDAS correlated with DAS28 at r=0.94 (95% CI 0.92-0.96), with Spearman rho=0.93 and an intraclass correlation coefficient of 0.94. The fitted relationship was DDAS = 0.99 x DAS28 + 0.07 (R²=0.89). Mean Bland-Altman bias was 0.02 points, with limits of agreement from -1.18 to +1.22. Exact four-band agreement was 78.8%, and weighted kappa was 0.88.
The smartphone-derived measure demonstrated strong concurrent association with clinician-assessed DAS28, small average numerical bias and substantial categorical and longitudinal concordance in this exploratory single-centre cohort.
How to Cite This Article
Khan NSA, Hughes N, Akram SJ, Faeq M. Concurrent validity and longitudinal responsiveness of a smartphone-derived disease activity measure in rheumatoid arthritis using clinician-assessed DAS28 as the reference standard. J Pak Soc Intern Med. 2026;7(4):294–299. doi:10.70302/jpsim.v7i4.2659
Conflict of Interest
The authors declare no conflict of interest.
Funding
This research received no specific grant from any funding agency.
Funder information follows the Crossref Funder Registry standard.
Author Contributions
NSAK: Conception.
SJA: Design of the work.
NH, MF: Data acquisition, analysis, or interpretation.
NH, SJA, MF: Draft the work.
NSAK: Review critically for important intellectual content.
All authors approve the version to be published.
All authors agree to be accountable for all aspects of the work.
Contributions are recorded against the ICMJE criteria for authorship.
Data Availability
Data are available from the corresponding author on reasonable request.
Ethics Statement
This study was approved by IBR, PSIM Foundation, Lahore Pakistan. Approval number: AKC25/SYN0726, dated October 21, 2025.
Conducted in accordance with the Declaration of Helsinki.
References
- Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen . Validation of the 28-joint Disease Activity Score (DAS28) and EULAR response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis. Ann Rheum Dis. 2009;68(6):954-60.
- Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham C. rheumatoid arthritis classification criteria: an ACR/EULAR collaborative initiative. Arthritis Rheum. 2010;62(9):2569-81.
- Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St. Clair EW, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the TEAR trial. Arthritis Rheum. 2012;64(9):2824-35.
- Smolen JS, Aletaha D, Bijlsma JWJ. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631-7.
- Orbai AM, Bingham CO III. Patient reported outcomes in rheumatoid arthritis clinical trials. Curr Rheumatol Rep. 2015;17(4):28.
- Nishiguchi S, Ito H, Yamada M, Yoshitomi H, Furu M, Ito T, et al. Self-assessment tool of disease activity of rheumatoid arthritis by using a smartphone application. Telemed J E Health. 2014;20(3):235-240.
- Nishiguchi S, Ito H, Yamada M, Yoshitomi H, Furu M, Ito M, et al. Self-assessment of rheumatoid arthritis disease activity using a smartphone application: development and 3-month feasibility study. Methods Inf Med. 2016;55(1):65-9.
- Espinoza F, Le Blay P, Coulon D, Lieu S, Munro J, Jorgensen C, Pers YM. Handgrip strength measured by a dynamometer connected to a smartphone: a new applied health technology solution for self-assessment of rheumatoid arthritis disease activity. Rheumatol (Oxford). 2016;55(5):897-901.
- van Riel P, Alten R, Combe B, Abdulganieva D, Bousquet P, Courtenay M, et al. Improving inflammatory arthritis management through tighter monitoring and innovative electronic tools. RMD Open. 2016;2(2):e000302.
- Seppen BF, L'ami MJ, Duarte Dos Santos Rico S. Feasibility of self-monitoring rheumatoid arthritis with a smartphone app: results of two mixed-methods pilot studies. JMIR Form Res. 2020;4(9):e20165.
- Seppen B, Wiegel J, ter Wee MM. Smartphone-assisted patient-initiated care versus usual care in rheumatoid arthritis and low disease activity: a randomized controlled trial. Arthritis Rheumatol. 2022;74(11):1737-45.
- Colls J, Lee YC, Xu C, Corrigan C, Lu F, Marquez-Grap, et al. Patient adherence with a smartphone app for patient-reported outcomes in rheumatoid arthritis. Rheumatology (Oxford). 2021;60(1):108-12.
- Lee YC, Lu F, Colls J, Luo D, Wang P, Dunlop DD, et al. Outcomes of a mobile app to monitor patient-reported outcomes in rheumatoid arthritis: a randomized controlled trial. Arthr Rheumatol. 2021;73(8):1421-9.
- Najm A, Nikiphorou E, Kostine M. EULAR points to consider for development, evaluation and implementation of mobile health applications aiding self-management in rheumatic and musculoskeletal diseases. RMD Open. 2019;5:e001014.
- Creagh AP, Hamy V, Yuan H, Mertes G, Tomlinson R, Chen WH, et al. Digital health technologies and machine learning augment patient-reported outcomes to remotely characterise rheumatoid arthritis. NPJ Digit Med. 2024;7(1):33.
- Arumalla N, Chan CK, Gibson M, Man YL, Adas MA, Norton S, et al. Clinical impact of electronic patient-reported outcome measures in remote monitoring of inflammatory arthritis: systematic review and meta-analysis. Arthritis Rheumatol. 2023;75(11):1892-903.
- Austin L, Sharp CA, van der Veer SN. Providing the bigger picture: benefits and feasibility of integrating remote monitoring from smartphones into the electronic health record. Rheumatol (Oxford). 2020;59(2):367-78.
- Watson K, Sheldon H, Pallari E, Arumalla N, Olive RR, Boiko O, et al. Remote monitoring of patients with rheumatoid arthritis in a low disease activity state: a mixed-methods evaluation across six hospitals in London, UK. Rheumatol (Oxford). 2024;63(10):2721-33.
- McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012;22(3):276-282.
- Kottner J, Audige L, Brorson S, Donner A, Gajewski BJ, Hróbjartsson A, et al. Guidelines for Reporting Reliability and Agreement Studies (GRRAS). J Clin Epidemiol. 2011;64(1):96-106.
- Collins GS, Dhiman P, Andaur Navarro CL. Protocol for development of a reporting guideline for artificial intelligence-based clinical prediction models: TRIPOD+AI. BMJ. 2024;385:e078378.
- Naeem F, Khan SE, Saeed MA, Farman S. Diagnostic and therapeutic delay in rheumatoid arthritis patients: impact on disease outcome. Pak J Med Sci. 2021;37(4):1001-7.
- Wagan AA, Raheem A, Bhatti A. Fatigue assessment by FACIT-F scale in Pakistani cohort with rheumatoid arthritis: the FAF-RA study. Pak J Med Sci. 2021;37(4):1025-30.
- Jalil F, Yaqoob M, Khaliq A. Progression pattern of rheumatoid arthritis: a study of 500 Pakistani patients. Pak J Pharm Sci. 2017;30(4):1219-23.
Reference list indexed for Google Scholar and ResearchGate. DOI links resolve via doi.org.